Cancer Medicine: review time and acceptance speed
ISSN 2045-7634 · Wiley · Medicine
Half of the articles Cancer Medicine accepted in 2025 were accepted within 169 days of submission (n = 883); the middle half took 117–244 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Cancer Medicine take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2025 | 883 | 117 | 169 | 244 | 326 | 0.0% | 100% |
| 2024 | 1,029 | 106 | 152 | 204 | 267 | 0.1% | 99% |
| 2023 | 1,270 | 93 | 128 | 184 | 255 | 0.3% | 99% |
| 2022 | 987 | 84 | 120 | 171 | 222 | 0.4% | 99% |
| 2021 | 786 | 64 | 97 | 144 | 225 | 0.2% | 97% |
| 2020 | 836 | 69 | 101 | 140 | 190 | 0.8% | 97% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 180 days after it ends).
Research articles vs reviews (2025)
| Type | n | 25th pct | Median | 75th pct |
|---|---|---|---|---|
| Research articles | 734 | 118 | 171 | 249 |
| Reviews | 149 | 109 | 150 | 223 |
Distribution in 2025
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 2 | 0.2% |
| 30–59 | 23 | 2.6% |
| 60–89 | 80 | 9.1% |
| 90–119 | 133 | 15.1% |
| 120–149 | 135 | 15.3% |
| 150–179 | 114 | 12.9% |
| 180–209 | 84 | 9.5% |
| 210–239 | 86 | 9.7% |
| 240–269 | 60 | 6.8% |
| 270–299 | 47 | 5.3% |
| 300–329 | 35 | 4.0% |
| 330–359 | 27 | 3.1% |
| 360+ | 57 | 6.5% |
From acceptance to online publication
Not enough articles with both an acceptance date and an online publication date to measure the time to online publication.
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Open access (listed in DOAJ). Listed APC: $4,970 (DOAJ).
Institutions reported paying a median of about $3,330 per article (2023–2025, 19 reported payments in OpenAPC; converted from euros at yearly ECB average rates).
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | Yes (DOAJ record) |
|---|---|
| Articles indexed for MEDLINE in 2025 | Yes |
| Retractions | 2 retracted articles among 4,989 added to PubMed in 2021–2025 (0.40 per 1,000), per the Retraction Watch Database. |
| Accepted within 14 days of submission | 0.0% of 2025 articles |
| Publication volume | 936 articles added to PubMed in 2025 (-10% vs 2024). |
Topics and scope
- Cancer Immunotherapy and Biomarkers (8% of indexed topics)
- Cancer survivorship and care (6% of indexed topics)
- Ferroptosis and cancer prognosis (6% of indexed topics)
- Global Cancer Incidence and Screening (5% of indexed topics)
- Lung Cancer Treatments and Mutations (5% of indexed topics)
- Head and Neck Cancer Studies (5% of indexed topics)
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2025 figures are compared with the 2025 median of Cancer Medicine, 169 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| BMC Cancer | 132 (2025, n = 2,045) | $3,550 | $3,079 (27 payments) | Yes | Yes |
| Translational Cancer Research | 109 (2025, n = 625) | — | — | No | No |
| Frontiers in Oncology | 99 (2025, n = 4,517) | ≈$3,850 | $3,497 (212 payments) | Yes | No |
| World Journal of Clinical Oncology | 96 (2025, n = 218) | — | — | No | No |
| Cancer Research and Treatment | 107 (2025, n = 167) | — | — | No | Yes |
| Annals of Translational Medicine | 99 (2025, n = 50) | — | — | No | No |
| Current Oncology | 45 (2025, n = 692) | ≈$2,689 | $2,146 (29 payments) | Yes | Yes |
| Clinical & Translational Oncology | 65 (2025, n = 349) | ≈$4,690 | — | No | Yes |
| Clinical Medicine Insights Oncology | 138 (2025, n = 64) | $2,650 | — | Yes | No |
| Therapeutic Advances in Medical Oncology | 118 (2025, n = 271) | $2,800 | — | Yes | No |
No journals match these filters.
Frequently asked questions
How long does Cancer Medicine take to accept a paper?
Half of the articles Cancer Medicine accepted in 2025 were accepted within 169 days of submission (n = 883); the middle half took 117–244 days. Based on dates in PubMed for accepted articles only.
Does Cancer Medicine charge an article processing charge (APC)?
Listed APC: $4,970 (DOAJ).
Sources and method
Journal identity: ISSN-L 2045-7634; NLM ID 101595310; OpenAlex record. Speed figures use 883 articles accepted in 2025 with valid dates; excluded records for that year: none.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.